Online workshop: Understanding access and reimbursement
Getting wider access to drugs for as many patients a possible is a clear priority in the drug development process, especially for patient groups who are working to secure research […]
Getting wider access to drugs for as many patients a possible is a clear priority in the drug development process, especially for patient groups who are working to secure research […]
Researchers developing new treatments for children with rare brain tumours know that it’s not a case of treating children like tiny adults and that surviving the disease isn’t enough. Reducing […]
Every person has two copies of each gene, one inherited from each parent. Most genes are the same in all people, but a small number of them are slightly different. […]
Medics4RareDiseases (M4RD) is happy to announce it has collaborated with Bionical Emas, a global Contract Research Organisation, to launch new online training for healthcare professionals. The mini-module is comprised of […]
Fibular Hemimelia is a rare congenital condition characterised by the complete or partial absence of the fibula bone. It is the same condition which afflicted athletes Aimee Mullins and Oscar […]
Spring is in the air and the team at M4RD have been reflecting on what has been a HUGE first quarter for us. Most notably, we have grown. Melissa, our […]
M4RD is proud to be collaborating on Phase 3 of the I am number 17 campaign in order to reach a vital audience who can make a huge difference to those […]
Our Ambassador Programme is now open to new applications – this is your chance to become an M4RD Ambassador and a rare disease ally! About our programme Our ambassador programme […]
Join this webinar to explore the practical things patient groups can do to make sure they are engaging with HCPs in the most beneficial way. Most rare diseases are not […]
This FREE live 90-minute webinar will focus on the diagnosis and management of rare diseases, in particular haematological conditions. The fundamentals of a rare disease – what is it? Who […]